Pseudoxanthoma Elasticum
27
7
8
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
4%
1 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (27)
Purinergic Compounds in Pseudoxanthoma Elasticum
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum
Progression Assessment of PXE-associated Alterations
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Impact of Optimized Recruitment and Follow-up of Patients with Pseudoxanthoma Elasticum (PXE)
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
PPI Supplementation to Fight ECtopIc Calcification in PXE
The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum
Employment of Patients With Pseudoxanthoma Elasticum
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
Oral Pyrophosphate Absorption in PXE Disease
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
Natural History of GACI With or Without ARHR2 or PXE
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum